Subscribe To
SGEN / Strength Seen in Seattle Genetics (SGEN): Can Its 14.5% Jump Turn into More Strength?
SGEN News
By Proactive Investors
November 1, 2023
Seagen 3Q revenue beat driven by jump in product sales
Seagen reported mixed third quarter earnings, with revenue outperforming expectations on strong product sales growth as earnings fell short of estimat more_horizontal
By Schaeffers Research
September 25, 2023
Signal Says Buy Calls on This Biotech Stock
Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and more_horizontal
By Zacks Investment Research
September 25, 2023
Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study
Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metas more_horizontal
By Zacks Investment Research
August 17, 2023
Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal
Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla. more_horizontal
By Reuters
August 16, 2023
Seagen's breast cancer therapy meets main goal in late-stage study
Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease pro more_horizontal
By The Motley Fool
May 24, 2023
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
There isn't much overlap between Amgen's business and Horizons', but that isn't stopping the FTC from looking to block the deal. Pfizer has a strong o more_horizontal
By MarketBeat
May 19, 2023
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Pfizer Inc. NYSE: PFE continued its downward trajectory on May 17, following news that the Federal Trade Commission is seeking to block Amgen Inc.'s N more_horizontal
By CNBC
May 17, 2023
Pfizer to raise $31 billion in debt offering to fund Seagen acquisition, SEC filing shows
The debt offering by Pfizer to buy cancer drug maker Seagen comes as Apple, Merck and T-Mobile tap the U.S. bond market ahead of the debt ceiling stan more_horizontal